Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long- Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Purpose: To investigate the surgical, perfusion, and molecular characteristics of glioblastomas which influence long-term survival after treatment, and to explore the association between MR perfusion parameters and the presence of MGMT methylation and 1p/19q deletions. Materials and Methods: This retrospective study was approved by our institutional review board. A total 43 patients were included, all with pathologic diagnosis of glioblastoma with known MGMT methylation and 1p/19q deletion statuses. We divided these patients into longterm (≥ 60 months, n = 7) and short-term (< 60 months, n = 36) survivors, then compared surgical extent, molecular status, and rCBV parameters between the two groups using Fisher’s exact test or Mann-Whitney test. The rCBV parameters were analyzed according to the presence of MGMT methylation and 1p/19q deletions. We investigated the relationship between the mean rCBV and overall survival using linear correlation. Multivariable linear regression was performed in order to find the variables related to overall survival. Results: Long-term survivors (100% [7 of 7]) demonstrated a greater percentage of gross total or near total resection than short-term survivors (54.5% [18 of 33]). A higher prevalence of 1p/19q deletions was also noted among the long-term survivors (42.9% [3 of 7]) than the short-term survivors (0.0% [0 of 36]). The rCBV parameters did not differ between the longterm and short-term survivors. The rCBV values were marginally lower in patients with MGMT methylation and 1p/19q deletions. Despite no correlation found between overall survival and rCBV in the whole group, the short-term survivor group showed negative correlation (R2 = 0.181, P = 0.025). Multivariable linear regression revealed that surgical extent and 1p/19q deletions, but not rCBV values, were associated with prolonged overall survival. Conclusion: While preoperative rCBV and 1p/19q deletion status are related to each other, only surgical extent and the presence of 1p/19q deletion in GBM patients may predict longterm survival.
Abstract
Purpose: To investigate the surgical, perfusion, and molecular characteristics of glioblastomas which influence long-term survival after treatment, and to explore the association between MR perfusion parameters and the presence of MGMT methylation and 1p/19q deletions. Materials and Methods: This retrospective study was approved by our institutional review board. A total 43 patients were included, all with pathologic diagnosis of glioblastoma with known MGMT methylation and 1p/19q deletion statuses. We divided these patients into longterm (≥ 60 months, n = 7) and short-term (< 60 months, n = 36) survivors, then compared surgical extent, molecular status, and rCBV parameters between the two groups using Fisher’s exact test or Mann-Whitney test. The rCBV parameters were analyzed according to the presence of MGMT methylation and 1p/19q deletions. We investigated the relationship between the mean rCBV and overall survival using linear correlation. Multivariable linear regression was performed in order to find the variables related to overall survival. Results: Long-term survivors (100% [7 of 7]) demonstrated a greater percentage of gross total or near total resection than short-term survivors (54.5% [18 of 33]). A higher prevalence of 1p/19q deletions was also noted among the long-term survivors (42.9% [3 of 7]) than the short-term survivors (0.0% [0 of 36]). The rCBV parameters did not differ between the longterm and short-term survivors. The rCBV values were marginally lower in patients with MGMT methylation and 1p/19q deletions. Despite no correlation found between overall survival and rCBV in the whole group, the short-term survivor group showed negative correlation (R2 = 0.181, P = 0.025). Multivariable linear regression revealed that surgical extent and 1p/19q deletions, but not rCBV values, were associated with prolonged overall survival. Conclusion: While preoperative rCBV and 1p/19q deletion status are related to each other, only surgical extent and the presence of 1p/19q deletion in GBM patients may predict longterm survival.
참고문헌 (38)
- Affronti ML, "Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy", Cancer, 115, pp.3501~3511 (2009)[DOI]
- Ostrom QT, "Response to "the epidemiology of glioma in adults: a 'state of the science' review"", Neuro Oncol, 17, pp.624~626 (2015)[DOI]
- Buckner JC, "Factors influencing survival in high-grade gliomas", Semin Oncol, 30, pp.10~14 (2003)[DOI]
- Curran WJ Jr, "Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials", J Natl Cancer Inst, 85, pp.704~710 (1993)[DOI]
- DeAngelis LM, "Brain tumors", N Engl J Med, 344, pp.114~123 (2001)[DOI]
- Newlands ES, "Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials", Cancer Treat Rev, 23, pp.35~61 (1997)[DOI]
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide forglioblastoma", N Engl J Med, 352, pp.987~996 (2005)[DOI]
- Yung WK, "A phase II study of temozolomide vs. procarbazine in patients withglioblastoma multiforme at first relapse", Br J Cancer, 83, pp.588~593 (2000)[DOI]
- Stupp R, "Current and future developments in the use of temozolomide for the treatment of brain tumours", Lancet Oncol, 2, pp.552~560 (2001)[DOI]
- Louis DN, "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary", Acta Neuropathol, 131, pp.803~820 (2016)[DOI]
- Johnson DR, "2016 updates to the WHO brain tumor classification system: what the radiologist needs to know", Radiographics, 37, pp.2164~2180 (2017)[DOI]
- Wesseling P, "WHO 2016 classification of gliomas", Neuropathol Appl Neurobiol, 44, pp.139~150 (2018)[DOI]
- Hegi ME, "Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation inglioblastoma patients treated with temozolomide", Clin Cancer Res, 10, pp.1871~1874 (2004)[DOI]
- Zhao J, "Loss of heterozygosity 1p", 19q and survival in glioma: a meta-analysis, 2014, pp.16, 103~112
- Moon WJ, "Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging", Neuroradiology, 54, pp.555~563 (2012)[DOI]
- 김병섭, "Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea", Cancer Research and Treatment, 49(1), pp.193~203 (2017), 대한암학회
- Wesseling P, "Oligodendroglioma: pathology, molecular mechanisms and markers", Acta Neuropathol, 129, pp.809~827 (2015)[DOI]
- Blanc JL, "Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas", J Neurooncol, 68, pp.275~283 (2004)[DOI]
- 김성호, "Measurement of Apparent Diffusion Coefficient Values from Diffusion-Weighted MRI: A Comparison of Manual and Semiautomatic Segmentation Methods", Investigative Magnetic Resonance Imaging, 19(2), pp.88~98 (2015), 대한자기공명의과학회[DOI]
- 김예은, "Differentiation between Glioblastoma and Primary Central Nervous System Lymphoma Using Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging: Comparison Study of the Manual versus Semiautomatic Segmentation Method", Investigative Magnetic Resonance Imaging, 21(1), pp.9~19 (2017), 대한자기공명의과학회[DOI]
- Aronen HJ, "Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings", Radiology, 191, pp.41~51 (1994)[DOI]
- Bag AK, "Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters", J Neurooncol, 120, pp.361~370 (2014)[DOI]
- Choi SH, "Perfusion MRI as the predictive", prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis, 2016, pp.128, 185~194
- Brown TJ, "Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis", JAMA Oncol, 2, pp.1460~1469 (2016)[DOI]
- Qaddoumi I, "Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price?", Cancer, 116, pp.5461~5469 (2010)[DOI]
- Cairncross G, "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402", J Clin Oncol, 31, pp.337~343 (2013)
- Eckel-Passow JE, "Glioma groups based on 1p", 19q, IDH, and TERT promoter mutations in tumors, 2015, pp.372, 2499~2508
- Jenkins RB, "A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma", Cancer Res, 66, pp.9852~9861 (2006)[DOI]
- van den Bent MJ, "Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951", J Clin Oncol, 31, pp.344~350 (2013)
- Kaneshiro D, "Chromosome 1p and 19q deletions in glioblastoma multiforme", Appl Immunohistochem Mol Morphol, 17, pp.512~516 (2009)[DOI]
- Aum DJ, "Molecular and cellular heterogeneity: the hallmark of glioblastoma", Neurosurg Focus, 37, pp.E11~ (2014)
- Meng W, "Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta- analysis", Cancer Manag Res, 9, pp.411~425 (2017)[DOI]
- Stecco A, "Prognostic value of relative cerebral blood volume (rCBV) in patients with recurrent glioblastoma multiforme treated with bevacizumab", J Neurosurg Sci (2016)
- Law M, "Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging", Radiology, 247, pp.490~498 (2008)[DOI]
- Sawlani RN, "Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study", Radiology, 255, pp.622~628 (2010)[DOI]
- Cha S, "Differentiation of low- grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging", AJNR Am J Neuroradiol, 26, pp.266~273 (2005)
- Jenkinson MD, "Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours", Neuroradiology, 48, pp.703~713 (2006)[DOI]
- Bonekamp D, "Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques", J Magn Reson Imaging, 42, pp.87~96 (2015)[DOI]